Potential drug–drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals
Jackson Mukonzo, Eleni Aklillu, Vincent C. Marconi, Raymond F. Schinazi
International Journal of Infectious Diseases · 2019-04
Abstract
HIV-positive TB co-infected patients are at increased risk of multidrug-resistant (MDR)-TB compared to HIV-negative patients. Co-treatment of MDR-TB and HIV is common particularly in Sub-Saharan Africa where the co-morbidity is endemic. We discuss potential cellular metabolic pathway-mediated drug-drug interactions and the possible effect on HIV treatment outcomes of commonly prescribed antiretroviral therapy.
MeSH terms
- Tuberculosis
- Drug
- Medicine
- Human immunodeficiency virus (HIV)
- Antiretroviral therapy
- Drug resistance
- Antiretroviral drug
- Multiple drug resistance
- Extensively drug-resistant tuberculosis
- Pharmacotherapy
- Pharmacology
- Intensive care medicine
- Mycobacterium tuberculosis